New KRAS Inhibitor Showed Potential in Cancer Models

Researchers in San Diego shared data on an experimental drug that targeted mutated proteins in pancreatic and other cancers.

Updated on Sept. 28, 2026 in Cancer

Isometric editorial illustration of a complex protein structure composed of interconnected geometric spheres, representing molecular research. — BlossomHill Therapeutics presented new preclinical data for their experimental drug, BH-501284, showing potential tumor regression in KRAS-mutant cancer models. AI Illustration. Upload story photo >

Live Poll

Do you believe pharmaceutical companies are making sufficient progress in developing treatments for difficult cancers?

BlossomHill Therapeutics presented new preclinical data for their experimental drug, BH-501284, at the AACR Conference on Pancreatic Cancer. The drug demonstrated tumor regression in various KRAS-mutant cancer models, marking a potential step toward new treatment options.

Why it matters

This drug is designed to address existing limitations in KRAS-targeted therapies by improving both efficacy and tolerability. By potentially offering a more durable response in KRAS-mutant tumors, it aims to provide a new pathway for patients currently facing few standard options.

In a preclinical surface plasmon resonance (SPR) study, BH-501284 achieved a target residence time of over 54 hours. The drug demonstrated deeper and more durable tumor regression in KRAS G12D pancreatic cancer models compared to existing tricomplex RAS inhibitors.

The players

BlossomHill Therapeutics

A San Diego-based biotechnology company focused on developing novel small-molecule inhibitors for oncology.

The details

The drug utilizes a novel Switch-II chemical scaffold to achieve pseudo-irreversible binding to the KRAS protein. By specifically targeting KRAS signaling while sparing HRAS and NRAS, the therapy minimizes off-target effects. This mechanism was paired with anti-PD-1 treatment in experiments, which resulted in prolonged survival in colorectal cancer models compared to either therapy alone.

September 25-28, 2026: AACR Conference on Pancreatic Cancer took place in San Diego.
Q1 2027: Planned submission of an Investigational New Drug application for BH-501284.

Health Landscape

This development represents an attempt to improve upon the current limitations found in the development of KRAS-targeted therapies. It specifically aims to move beyond current constraints in targeting the KRAS protein by utilizing a novel pseudo-irreversible binding mechanism.

This research is currently in the preclinical stage and is not yet available for patient care. If you are currently navigating a cancer diagnosis involving KRAS mutations, discuss available clinical trials and the latest approved targeted therapies with your oncologist.

The takeaway

While preclinical results in tumor models are promising, they do not guarantee success in future human clinical trials. Patients should continue to work closely with their medical team to identify the most appropriate, evidence-based treatment options currently available for their specific diagnosis.